Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ACACA | Q13085 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880027 | 0.86 | AR (0.53) | AR | |
| SCHEMBL27714512 | 0.81 | AR (0.56) | AR | |
| SCHEMBL4235266 | 0.81 | AR (0.45) | ARNSD2 | |
| SCHEMBL3603145 | 0.81 | PIM1 (0.54) | ARNSD2CKS1BSKP1SKP2 | |
| SCHEMBL10231567 | 0.80 | AR (0.48) | ARPRMT5IRAK1DRD2NAMPT | |
| SCHEMBL14206394 | 0.80 | DRD2 (0.49) | PRMT5IRAK1DRD2NAMPTCKS1B | |
| Hydrochloric Acid SCHEMBL4881079 | 0.80 | AR (0.55) | AR | |
| SCHEMBL10232262 | 0.80 | NAMPT (0.55) | PRMT5IRAK1DRD2NAMPTCKS1B | |
| SCHEMBL24986986 | 0.79 | CKS1B (0.56) | DRD2CKS1BSKP1SKP2ACACB | |
| SCHEMBL29717179 | 0.79 | IRAK1 (0.44) | PRMT5IRAK1DRD2NAMPTCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | claimed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | AR 2/4885PRMT5 1199/4885IRAK1 1804/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | AR 2/4885PRMT5 1276/4885IRAK1 1749/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | AR 2/4885PRMT5 1199/4885IRAK1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.